Genomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones
Start here
SCID-rab patient-derived xenografts expanded scarce primary multiple myeloma samples across disease stages and cytogenetic subgroups while retaining genomic, transcriptomic and proteomic features of the patient tumors, including abundant CD138+ cells. WGS and single-cell WGS showed the xenografts arose by selection of pre-existing subclones, some harboring high-risk alterations and convergent tumor suppressor inactivation. The models also matched primary MM more closely than myeloma cell lines in proliferative state and therapeutic target expression.
Excerpted from biorxiv.org
Coverage timeline
Follow the coverage to see the different angles.
- biorxiv.orgPickGenomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones
SCID-rab patient-derived xenografts expanded scarce primary multiple myeloma samples across disease stages and cytogenetic subgroups while retaining genomic, transcriptomic and proteomic features of the patient tumors, including abundant CD138+ cells. WGS and single-cell WGS showed the xenografts arose by selection of pre-existing subclones, some harboring high-risk alterations and convergent tumor suppressor inactivation. The models also matched primary MM more closely than myeloma cell lines in proliferative state and therapeutic target expression.
Heat trend for this story
Not enough continuous observation yet to draw a trend.